Literature DB >> 21881597

Low-dose atorvastatin reduces ambulatory blood pressure in patients with mild hypertension and hypercholesterolaemia: a double-blind, randomized, placebo-controlled study.

A I Kanaki1, P A Sarafidis, P I Georgianos, P C Stafylas, K Kanavos, I M Tziolas, A N Lasaridis.   

Abstract

Among several beneficial cardiovascular actions of statins, experimental studies have suggested that statins may also induce a mild blood pressure (BP) reduction. However, clinical data were controversial and the potential hypotensive statin effect remains uncertain. This study aimed to investigate the effect of atorvastatin on ambulatory BP in patients with mild hypertension and hypercholesterolaemia. A total of 50 patients with mild hypertension and hypercholesterolaemia participated in this double-blind, randomized, placebo-controlled study. Patients were randomized to either 10 mg atorvastatin or placebo for 26 weeks. Background antihypertensive treatment, if any, remained unchanged during follow-up. At baseline and study-end (26 weeks), ambulatory BP monitoring and blood sampling for determination of standard biochemical and safety parameters were performed in all participants. BP loads were defined as the percentage of BP measurements exceeding the hypertension threshold of 140/90 mm Hg for daytime and 125/75 mm Hg nighttime period. Atorvastatin significantly reduced 24-h systolic and diastolic BP (DBP; median (range)) as compared with placebo (-5.0 (-21.0, 4.0) vs +1.0 (-6.0, 7.0) mm Hg, P<0.001 and -3.0 (-16.0, 2.0) vs +0.1 (-7, 4) mm Hg, P<0.01, respectively). Reductions in systolic and DBP loads during follow-up were also evident in the atorvastatin, but not in the placebo group. BP-lowering effects of atorvastatin were consistent in both daytime and nighttime periods. This study shows a mild, but consistent throughout the 24-h period BP-lowering effect of atorvastatin in patients with mild hypertension and hypercholesterolaemia. This beneficial effect of atorvastatin on BP may represent another pathway through which this drug class provides cardiovascular risk reduction.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21881597     DOI: 10.1038/jhh.2011.80

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  8 in total

1.  Impact of Statin Therapy on the Blood Pressure-Lowering Efficacy of a Single-Pill Perindopril/Amlodipine Combination in Hypertensive Patients with Hypercholesterolemia.

Authors:  Yuriy Sirenko; Ganna Radchenko
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-02-02

Review 2.  Future Treatment of Hypertension: Shifting the Focus from Blood Pressure Lowering to Arterial Stiffness Modulation?

Authors:  Henry Fok; J Kennedy Cruickshank
Journal:  Curr Hypertens Rep       Date:  2015-08       Impact factor: 5.369

3.  Lipophilic Statins and Aldosterone Secretion: A Bridge Too Far?

Authors:  Charlotte Andersson; Ramachandran S Vasan
Journal:  Circulation       Date:  2015-10-02       Impact factor: 29.690

4.  Blood pressure-lowering effect of simvastatin: a placebo-controlled randomized clinical trial with 24-h ambulatory blood pressure monitoring.

Authors:  V Correa; F D Fuchs; L B Moreira; M Gerhardt; S C Fuchs; C R Sloczinski; R G Monteggia; M Gus
Journal:  J Hum Hypertens       Date:  2013-05-16       Impact factor: 3.012

5.  Effects of different statin types and dosages on systolic/diastolic blood pressure: Retrospective analysis of 24-hour ambulatory blood pressure database.

Authors:  Vivianne Presta; Ilaria Figliuzzi; Barbara Citoni; Francesca Miceli; Allegra Battistoni; Maria Beatrice Musumeci; Roberta Coluccia; Luciano De Biase; Andrea Ferrucci; Massimo Volpe; Giuliano Tocci
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-04-23       Impact factor: 3.738

6.  Antihypertensive effects of statins: a meta-analysis of prospective controlled studies.

Authors:  Alexandros Briasoulis; Vikram Agarwal; Antonis Valachis; Franz H Messerli
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-03-07       Impact factor: 3.738

7.  Integrating gene expression and clinical data to identify drug repurposing candidates for hyperlipidemia and hypertension.

Authors:  Patrick Wu; QiPing Feng; Vern Eric Kerchberger; Scott D Nelson; Qingxia Chen; Bingshan Li; Todd L Edwards; Nancy J Cox; Elizabeth J Phillips; C Michael Stein; Dan M Roden; Joshua C Denny; Wei-Qi Wei
Journal:  Nat Commun       Date:  2022-01-10       Impact factor: 17.694

8.  Atorvastatin and sildenafil decrease vascular TGF-β levels and MMP-2 activity and ameliorate arterial remodeling in a model of renovascular hypertension.

Authors:  Danielle A Guimarães; Elen Rizzi; Carla S Ceron; Alisson Martins-Oliveira; Raquel F Gerlach; Sruti Shiva; Jose E Tanus-Santos
Journal:  Redox Biol       Date:  2015-08-31       Impact factor: 11.799

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.